Cargando…

High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals

Recently identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants Mu and C.1.2 have spike proteins with mutations that may confer resistance to natural and vaccine-elicited antibodies. Analysis of neutralizing antibody titers in the sera of vaccinated individuals without prev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tada, Takuya, Zhou, Hao, Dcosta, Belinda M., Samanovic, Marie I., Cornelius, Amber, Herati, Ramin S., Mulligan, Mark J., Landau, Nathaniel R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. 2022
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687746/ https://www.ncbi.nlm.nih.gov/pubmed/34982967 http://dx.doi.org/10.1016/j.celrep.2021.110237

Ejemplares similares

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
por: Tada, Takuya, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
por: Zhou, Hao, et al.
Publicado: (2021)

Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera
por: Tada, Takuya, et al.
Publicado: (2021)

Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies
por: Zhou, Hao, et al.
Publicado: (2022)

Prophylaxis and treatment of SARS-CoV-2 infection by an ACE2 receptor decoy in a preclinical animal model
por: Tada, Takuya, et al.
Publicado: (2023)

Single-epitope T cell–based vaccine protects against SARS-CoV-2 infection in a preclinical animal model
por: Tada, Takuya, et al.
Publicado: (2023)

High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens
por: Counoupas, Claudio, et al.
Publicado: (2022)

Robust immune responses after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals
por: Samanovic, Marie I., et al.
Publicado: (2021)

Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals
por: Samanovic, Marie I., et al.
Publicado: (2021)

Vaccine-Acquired SARS-CoV-2 Immunity versus Infection-Acquired Immunity: A Comparison of Three COVID-19 Vaccines
por: Samanovic, Marie I., et al.
Publicado: (2022)

Factors influencing neutralizing antibody titers elicited by coronavirus disease 2019 vaccines
por: Kung, Yu-An, et al.
Publicado: (2023)

Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults
por: Miyaji, Karina Takesaki, et al.
Publicado: (2017)

An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2
por: Tada, Takuya, et al.
Publicado: (2020)

BNT162b2 SARS-CoV-2 Vaccination Elicits High Titers of Neutralizing Antibodies to Both B.1 and P.1 Variants in Previously Infected and Uninfected Subjects
por: Vicenti, Ilaria, et al.
Publicado: (2021)

Multimodal characterization of antigen-specific CD8(+) T cells across SARS-CoV-2 vaccination and infection
por: Zhang, Bingjie, et al.
Publicado: (2023)

A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques.
por: Baisa, Gary, et al.
Publicado: (2021)

“A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques.”
por: Baisa, Gary, et al.
Publicado: (2020)

Multimodal single-cell datasets characterize antigen-specific CD8(+) T cells across SARS-CoV-2 vaccination and infection
por: Zhang, Bingjie, et al.
Publicado: (2023)

Low Neutralizing Antibody Titers against the Mu Variant of SARS-CoV-2 in 31 BNT162b2 Vaccinated Individuals in Colombia
por: Álvarez-Díaz, Diego A., et al.
Publicado: (2022)

Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities
por: Noval, Maria G., et al.
Publicado: (2021)

Vectored immunoprophylaxis and treatment of SARS-CoV-2 infection in a preclinical model
por: Tada, Takuya, et al.
Publicado: (2023)

Restriction of SARS-CoV-2 replication by receptor transporter protein 4 (RTP4)
por: Kaur, Ramanjit, et al.
Publicado: (2023)

Longitudinal antibody titer, avidity, and neutralizing responses after SARS-CoV-2 infection
por: Monroe, Jonathon M., et al.
Publicado: (2022)

SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination
por: Arora, Prerna, et al.
Publicado: (2022)

Kappa-RBD produced by glycoengineered Pichia pastoris elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants
por: Mi, Taotao, et al.
Publicado: (2022)

The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV
por: Cullen, Lori M., et al.
Publicado: (2017)

A Stabilized, Monomeric, Receptor Binding Domain Elicits High-Titer Neutralizing Antibodies Against All SARS-CoV-2 Variants of Concern
por: Ahmed, Shahbaz, et al.
Publicado: (2021)

Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection
por: Wolff, Marcelo J, et al.
Publicado: (2022)

Rapid determination of SARS-CoV-2 antibody neutralization titer using Bio-Rad Bio-Plex correlates strongly with pseudovirus-determined neutralization titer
por: Heaps, Amy L., et al.
Publicado: (2023)

Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses
por: Hellgren, Fredrika, et al.
Publicado: (2023)

Inflammation durably imprints memory CD4+ T cells
por: Gray-Gaillard, Sophie L., et al.
Publicado: (2023)

Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants
por: Padhiar, Nigam H., et al.
Publicado: (2022)

Correlation between Commercial Anti-RBD IgG Titer and Neutralization Titer against SARS-CoV-2 Beta Variant
por: Poon, Rosana Wing-Shan, et al.
Publicado: (2021)

A recombinant bovine herpesvirus-4 vectored vaccine delivered via intranasal nebulization elicits viral neutralizing antibody titers in cattle
por: Williams, Laura B. A., et al.
Publicado: (2019)

A combined strategy to detect plasma samples reliably with high anti-SARS-CoV-2 neutralizing antibody titers in routine laboratories
por: Fischer, Bastian, et al.
Publicado: (2021)

BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants
por: Liu, Jianying, et al.
Publicado: (2022)

Neutralization Titers in Vaccinated Patients with SARS-CoV-2 Delta Breakthrough Infections
por: Zou, Jing, et al.
Publicado: (2022)

Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity
por: Ross, Kathleen A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_raa92hc8ieb33lp4si63i68mt5